tbuckley/cabot-search huggingface dataset:
Prognostic impact of p53 compared to CEA and CA 19-9 in resectable colorectal cancer
Authors: Martin Gasser, Christiane Gerstlauer, Marco Bueter, Martin Grimm, Ulrich Maeder, Silke Hom, Ekatherine Nichiporuk, Andreas Thalheimer, Andreas Trumpfheller, Arnulf Thiede, Heinz-Jochen Gassel, Detlef Meyer, Ana Maria Waaga-Gasser
Journal: Cancer Research (2005)

1263    Background : Colorectal cancer (CRC) is a major cause of cancer-related deaths in the western world. This study was carried out to evaluate the prognostic significance of p53 compared to CEA (carcinoembryonic antigen) and CA 19-9 in order to predict the risk of tumor recurrence.  Methods : 783 patients from our center with confirmed CRC were evaluated retrospectively. The collective included only R0-resected stage I-III patients, those patients with metastases or a second carcinoma were excluded. Sex, age, location of the tumor, UICC stage with level of wall infiltration plus lymph node metastases, grading, CEA CA 19-9 and p53 were analyzed to determine the predictive value of the molecular markers (Kaplan-Meier, Chi-Quadrat-test). Preoperative blood samples were analyzed by Luminex (CEA and CA 19-9) and ELISA (p53). In addition, tumor specimens were assessed immunohistologically and by Real Time PCR.  Results : Preoperative CEA levels were significantly associated with staging (p=0,002), level of wall infiltaration (p 5 ng/ml (p=0,0044); interestingly, a better prognosis was observed in patients of UICC IIIA (p=0,0410). Furthermore, patients with colon cancer showed a lower relapse rate than those of the rectum (p=0,021). No predictive significance was observed for CA 19-9 and p53 (serum). In contrast, the expression of CA-19-9 and p53 as well as CEA in the tumor was dependent on the stage of the patients (CEA: UICC I/II 55,5%, III 100%; CA 19-9: UICC I/II 37,5%, III 80%; p53: UICC I/II 37,1%, III 57,1%) and combined with worse prognosis.  Conclusions : This study suggests that the preoperative CEA level combined with CA 19-9 and additional p53 in the tumor are suitable markers for stage III colorectal cancer patients, indicating that these patients should be considered as high risk group. Patients with a high score for p53, CEA, and CA 19-9 in this group may be the best candidates for an aggressive adjuvant therapy.
ATM role in prostate cancer (PrCa) progression and survival
Authors: Y. Cendón Flórez, P. Nombela Blanco, A. Medina, N. Romero Laorden, J. Puente, P.P. López Casas, A. Gutierrez Pecharromán, R. Sanchez-Escribano, L. Magraner, E. Gallardo Diaz, N. Lainez, P. Jiménez Gallego, R. Lozano Mejorada, E. Almagro Casado, R. Luque Caro, M. Domenech, A. Hernández Jorge, E. Castro Marcos, M.D.P. González-Peramato Gutierrez, D. Olmos Hidalgo
Journal: Annals of Oncology (2017)
Early FDG-PET response correlates with dose and clinical efficacy in patients with microsatellite stable (MSS) metastatic CRC (mCRC) treated with the CEA-CD3 T-cell bispecific antibody plus atezolizumab
Authors: F. Sandoval, D. Sabanes Bove, S. Bouseida, V. Karanikas, A. Keelara, J. Saro, T. Nayak
Journal: Annals of Oncology (2017)
Impact of chemotherapy (CT) in heavily pretreated BRCA1/2 mutation carrier ovarian cancer (BMCOC) patients (pts)
Authors: V. Rodriguez Freixinos, L. Fariñas Madrid, M. Gil Martin, P. Barretina, M. Romeo Marin, G. Villacampa Javierre, C. VIAPLANA, B. Pardo, H. Ahmed Ouahid, S. Recalde, J.M. Piulats Rodriguez, M.C. Gomez, A. Gil-Moreno, E. Sala, S. Martinez-Román, C. Melendez, E. Carballas, R. Dienstmann, A. Oaknin
Journal: Annals of Oncology (2017)
Estafilococos aureus resistentes à meticilina (EARM) na comunidade
Authors: J H T Wagenvoort, M Kepers-Rietrae
Journal: Eurosurveillance (1997)

Os Estafilococos aureus resistentes a meticilina (EARM) associados a infeccoes nosocomiais sao particularmente bem conhecidos (1) mas sabemos igualmente que eles estao na origem de infeccoes na comunidade (2). Definimos casos de infeccao por EARM na comunidade, pela deteccao de uma estirpe de EARM numa pessoa que nao tenha frequentado o meio hospitalar, internamento ou consulta, nos doze meses anteriores e que nunca tenha tido uma infeccao/contaminacao pelo EARM documentada. Ate ao presente, foram raros os casos declarados na Europa (1).
Pharmacokinetics and safety of BCD-022, trastuzumab biosimilar candidate, compared to Herceptin in patients.
Authors: Marina B. Stenina, Ekaterina Ignatova, Mona A. Frolova, Olga N. Burdaeva, Marina P. Nechaeva, Mikhail V. Kopp, Dmitry P. Udovitsa, Bogdan N. Kotiv, Sergiy M. Alekseev, Daniil L. Stroyakovsky, Ludmila P. Sheveleva, Andrey V. Khorinko, Tatiana I. Prokopenko, Julia S. Shapovalova, Irina A. Jelvakova, R. Ivanov, Olga V. Filon, Sergei Tjulandin
Journal: Journal of Clinical Oncology (2014)

e11576 Background: BCD-022 is a trastuzumab biosimilar candidate manufactured by CJSC BIOCAD, Russia. Full spectrum of physicochemical and preclinical studies showed equivalence of BCD-022 to innovator drug trastuzumab. Methods: 46 patients with HER2(+) mBC were enrolled in the study. Patients were randomly assigned into 2 groups at a ratio of 1:1 to receive BCD-022 or trastuzumab (a single loading dose 8 mg/kg a maintenance dose 6 mg/kg) with paclitaxel (175 mg/m2) every 3 weeks. The primary endpoint was AUC(0-504), the secondary endpoints included Cmax, T1/2 и Tmax. Trastuzumab serum concentrations were evaluated immediately before the first infusion and after 1.5 h, 3 h, 4.5 h, 6 h, 24 h, 96 h, 168 h, 336 h and 504 h. Results: PK analysis demonstrated that 90% CI for ratio of geometric means of AUC(0-504) of trastuzumab after single BCD-022 and trastuzumab administration was 80.42–120.87%, for ratio of Cmax– 83.69–123.05%. These ranges were within pre-specified PK equivalence criteria of 80–125 % according to EMA recommendations (EMA/CHMP/BMWP/403543/2010). There were no statistically significant differences between the groups for all other PK secondary parameters. BCD-022 and trastuzumab were well tolerated without any significant differences in AEs frequency between the groups. The most common AEs included hematological toxicity (leukopenia, neutropenia and anemia), hyperglycemia, AST, ALT, ALP and LDH increase. Arterial hypertension, tachycardia, alopecia, myalgia and arthralgia were less frequent. The majority of AEs were of Grade 1-2 (CTCAE 4.03) and were associated with myelosuppressive chemotherapy. Conclusions: PK and safety characteristics of BCD-022 and trastuzumab after a single i.v. administration in patients with HER2(+) mBC are considered to be equivalent. These data allow continue BCD-022 study aimed to assess efficacy and safety in the same population. Clinical trial information: NCT01764022.
A genome-wide CRISPR cell growth screen identifies NCAPG as a new therapeutic target for hepatocellular carcinoma
Authors: Y. Wang, B. Gao, P.Y. Tan, Y.A. Handoko, K. Sekar, A. Deivasigamani, V.P. Seshachalam, H.Y. OuYang, M. Shi, C. Xie, B.K. Poh Goh, L.L. Ooi, K.M. Hui
Journal: Annals of Oncology (2017)
Predictive factors in GEP-NEN: The integrated role of Ki67, beta-catenin and morphology
Authors: M. Milione, R. Miceli, A. Pellegrinelli, G. Centonze, F. Barretta, S. Pusceddu, L. Giacomelli, J. Coppa, V. Mazzaferro, G. Sozzi, A. Anichini, F. de Braud
Journal: Annals of Oncology (2017)
Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy
Authors: Elizabeth Smyth, Shenli Zhang, David Cunningham, Andrew Wotherspoon, Richie Soong, Clare Peckitt, Nicola Valeri, Matteo Fassan, Massimo Rugge, Alicia Okines, William Allum, Sally Stenning, Matthew Nankivell, Ruth Langley, Patrick Tan
Journal: Clinical Cancer Research (2017)

Abstract Purpose: Germline polymorphisms may affect chemotherapy efficacy and toxicity. We examined the effect of polymorphisms in drug metabolism and DNA repair genes on pathologic response rates, survival, and toxicity for patients randomized to surgery alone or perioperative ECF chemotherapy in the MRC MAGIC trial. Experimental Design: DNA was extracted from nontumor resection formalin-fixed paraffin-embedded (FFPE) blocks. ERCC1, ERCC2, XRCC1, DYPD, and OPRT SNPs were evaluated using Sequenom, GSTP1, GSTT1 deletion, and TYMS (TS) 5′ 2R/3R using multiplex PCR. Post PCR amplification, TS 2R/3R and GSTT1 samples underwent gel electrophoresis. Results: Polymorphism data were available for 289 of 456 (63.4%) operated patients. No polymorphism was statistically significantly associated with pathologic response to chemotherapy. Median overall survival (OS) for patients treated with surgery alone with any TS genotype was not different (1.76 years 2R/2R, 1.68 years 2R/3R, 2.09 years 3R/3R). Median OS for patients with a TS 2R/2R genotype treated with chemotherapy was not reached, whereas median OS for 2R/3R and 3R/3R patients were 1.44 and 1.60 years, respectively (log rank P value = 0.0053). The P value for the interaction between treatment arm and genotype (3R/3R and 3R/2R vs. 2R/2R) was 0.029. No polymorphism was statistically significantly associated with chemotherapy toxicity. Conclusions: In MAGIC, patients with a TS 2R/2R genotype appeared to derive a larger benefit from perioperative ECF chemotherapy than patients with 3R containing genotypes. Further exploration of this potential predictive biomarker in this patient population is warranted. Clin Cancer Res; 23(24); 7543–9. ©2017 AACR.
GW28-e1130 Cellular Repressor of E1A-stimulated Genes Promotes Smooth Muscle Cells Differentiation from Embryonic Stem Cells
Authors: Chengfei Peng, Xiaoping Shao, Xiaoxiang Tian, Chenghui Yan, Yaling Han, Wang Shuang
Journal: Journal of the American College of Cardiology (2017)
Th17 cytokines: novel potential therapeutic targets for COPD pathogenesis and exacerbations
Authors: Olivier Le Rouzic, Muriel Pichavant, Emilie Frealle, Antoine Guillon, Mustapha Si-Tahar, Philippe Gosset
Journal: European Respiratory Journal (2017)

Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease of the airways caused mainly by cigarette smoke exposure. COPD progression is marked by exacerbations of the disease, often associated with infections. Recent data show the involvement in COPD pathophysiology of interleukin (IL)-17 and IL-22, two cytokines that are important in the control of lung inflammation and infection. During the initiation and progression of the disease, increased IL-17 secretion causes neutrophil recruitment, leading to chronic inflammation, airways obstruction and emphysema. In the established phase of COPD, a defective IL-22 response facilitates pathogen-associated infections and disease exacerbations. Altered production of these cytokines involves a complex network of immune cells and dysfunction of antigen-presenting cells. In this review, we describe current knowledge on the involvement of IL-17 and IL-22 in COPD pathophysiology at steady state and during exacerbations, and discuss implications for COPD management and future therapeutic approaches.
Abstract #4318: Stable expression of the EBV-encoded LMP1 oncoprotein drives BJAB-cells to multinuclear phenotype and telomere aggregation
Authors: Hans Knecht, M Rowe, B Lemieux, Daniel Lichtenzstejn, Zelda Lichtenzstejn, B Sawan, Raymund Wellinger, Sabine Mai
Journal: Cancer Research (2009)

Stable expression of the LMP1 oncoprotein induces increase in cell size and expression of cellular adhesion molecules after 24-48 hours (1). We extended the induction period beyond 48 hours and examined stable LMP1 expression, nuclear volumes and 3D telomeric organization in interphase nuclei of BJAB Burkitt\#8217;s lymphoma cells at day 7, 10 and 21. Compared to non-LMP1 expressing BJAB cells, stable LMP1 expression led to an increase in nuclear volume (p    Citation Information:  In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 4318.
Bright spots, physical activity investments that work: JUMP-in: promoting physical activity and healthy nutrition at primary schools in Amsterdam
Authors: Vincent Busch, Paulus A J van Opdorp, Joshua Broek, Irene A Harmsen
Journal: British Journal of Sports Medicine (2017)

### Graphic programme card

Regular physical activity (PA) is vital to children’s health. Therefore, to battle its decline among Amsterdam’s children, in 2002 the intervention Jump-in was developed.1 Jump-in is a primary school-based, preventive intervention focused on stimulating children’s healthy nutrition and PA, especially targeting schools where overweight prevalence is highest. Jump-in schools stimulate children to be physically active and discover different types of sports and to stimulate their structural …
The continued emergence of hantaviruses: isolation of a Seoul virus implicated in human disease, United Kingdom, October 2012
Authors: L J Jameson, C H Logue, B Atkinson, N Baker, S E Galbraith, M W Carroll, T Brooks, R Hewson
Journal: Eurosurveillance (2013)

Following a suspected case of hantavirus in a patientsuffering from acute kidney injury, rodents fromthe patient’s property in Yorkshire and the Humber,United Kingdom (UK) were screened for hantaviruses.Hantavirus RNA was detected via RT-PCR in two Rattusnorvegicus. Complete sequencing and phylogeneticanalysis established the virus as a Seoul hantavirus,which we have provisionally designated as strainHumber. This is the first hantavirus isolated from wildrodents in the UK and confirms the presence of a pathogenicSeoul virus in Europe.
Prognostic impact of drug interactions in patients with advanced cancer
Authors: M. Joerger, A. Hömme, M. Haschke, S. Krähenbühl, F. Strasser, C. Lehner, A. von Kameke, T. Wälti, B. Thürlimann, M. Früh, C. Driessen
Journal: Annals of Oncology (2017)
Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance
Authors: Mark Owyong, Niloufar Hosseini-Nassab, Gizem Efe, Alexander Honkala, Renske J.E. van den Bijgaart, Vicki Plaks, Bryan Ronain Smith
Journal: Drug Resistance Updates (2017)
Expression of estrogen receptors and beta-III tubulin in non-small cell lung cancer tissue
Authors: E.A. Ponomarenko, I.A. Mamichev, T.A. Bogush, O.M. Ryabinina, J.B. Dyakova, D.V. Novikov, B.E. Polotsky, M.M. Davydov
Journal: Annals of Oncology (2017)
ATTRACTION-05 (ONO-4538-38/BMS CA209844): a randomized, multicenter, double-blind, placebo- controlled Phase 3 study of Nivolumab (Nivo) in combination with adjuvant chemotherapy in pStage III gastric and esophagogastric junction (G/EGJ) cancer
Authors: M. Terashima, Y-W. Kim, T-S. Yeh, H.C. Chung, J-S. Chen, N. Boku, Y-K. Kang, L-T. Chen, M. Sasako
Journal: Annals of Oncology (2017)
A risky political game with climate change
Authors: Mehdi Mirsaeidi, Abdy Javadzadeh, Michael Campos
Journal: European Respiratory Journal (2017)

Phrases and words such as "climate change", "global warming", "greenhouse effect", "depletion of the ozone layer", "rising sea levels" and "carbon footprint" have become part of the popular vernacular; household names, in a manner of speaking. We are all, to varying degrees, familiar with the viewpoints and ideas behind these concepts, and have had time to absorb and react to them. The way most of us have reacted can be gauged on a continuum. At one extreme, there are those who demonstrate a great deal of concern, and take personal, social, environmental and sometimes political action to correct a man-made phenomenon, and on the other side, there are those who do not care or pay much attention because they do not feel that climate change is really happening or is a direct effect of human action on Earth. In between, there are those who believe that climate change is a real phenomenon but that it will correct by itself. Physicians, biologists, and environmental and social scientists, as well as some politicians at local, state and federal levels, are the ones paying the highest attention to this ongoing environmental disaster. Unfortunately, despite ample and strong evidence about the reality of this issue, there are still those in positions of authority who live oblivious to the real magnitude of this problem. The health effects of climate change are serious challenges for physicians, scientists and politicians <http://ow.ly/ym2h30evYa4> M. Mirsaeidi conceived this editorial and performed the literature review. M. Mirsaeidi, A. Javadzadeh and M. Campos wrote the article or had substantial involvement in its revision before submission. The guarantor of this article is M. Mirsaeidi
Human Adenovirus Surveillance — United States, 2003–2016
Authors: Alison M. Binder, Holly M. Biggs, Amber K. Haynes, Christina Chommanard, Xiaoyan Lu, Dean D. Erdman, John T. Watson, Susan I. Gerber
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

Human adenoviruses (HAdVs) are nonenveloped, double-stranded DNA viruses in the family Adenoviridae; seven species (A-G) and >60 genotypes are known to cause human infection (1). Clinical manifestations associated with HAdV infection include fever, acute respiratory illness, gastroenteritis, and conjunctivitis. HAdV infection can be severe, particularly among immunocompromised patients, and can cause respiratory failure, disseminated infection, hemorrhagic cystitis, neurologic disease, and death (1,2). Illness tends to occur sporadically and without demonstrated seasonality. Outbreaks of HAdV have been reported globally in communities (3), and in closed or crowded settings, including dormitories, health care settings, and among military recruits, for whom a vaccine against HAdV type 4 (HAdV-4) and HAdV type 7 (HAdV-7) has been developed (4,5). CDC summarized HAdV detections voluntarily reported through the National Adenovirus Type Reporting System (NATRS) after initiation of surveillance in 2014 to describe trends in reported HAdVs circulating in the United States. Reporting laboratories were also encouraged to report available results for specimens collected before surveillance began. Overall, the number of reporting laboratories and HAdV type identifications reported to NATRS has increased substantially from the start of official reporting in 2014 through 2016; this report describes specimens collected during 2003-2016. The most commonly reported HAdV types were HAdV type 3 (HAdV-3) and HAdV type 2 (HAdV-2), although HAdV types reported fluctuated considerably from year to year. In the United States, information on recently circulating HAdV types is needed to inform diagnostic and surveillance activities by clinicians and public health practitioners. Routine reporting to NATRS by all U.S. laboratories with the capacity to type HAdVs could help strengthen this surveillance system.
Diversity of brain metastasis (BM) management in non-small cell lung cancer (NSCLC) in Europe (EU): Results of the Young Investigators European Organisation for Research and Treatment of Cancer Lung Cancer Group (YI EORTC LCG) survey
Authors: L. Hendriks, C. Faivre-Finn, B. Hasan, E. de Maio, A. Berghoff, A-M. Dingemans, S. Novello, T. Berghmans, B. Besse, A. Levy
Journal: Annals of Oncology (2017)
Antenatal screening and prevalence of infection: surveillance in London, 2000-2007
Authors: I Giraudon, J Forde, H Maguire, J Arnold, N Permalloo
Journal: Eurosurveillance (2009)

In the United Kingdom (UK), it is recommended to universally offer antenatal infection screening for human immunodeficiency virus (HIV), hepatitis B and syphilis infections, and susceptibility to rubella for the benefit of the mother and to reduce vertical transmission of infection. This paper describes the surveillance of antenatal infection including uptake of screening, and the results of testing in pregnant women in London between 2000 and 2007. Antenatal screening coordinators in liaison with midwifery heads and microbiologists at all thirty London National Health Service (NHS) Trust maternity units supplied quarterly data on the number of pregnant women booked for antenatal care, tests done, and tests results. The overall estimated uptake of screening increased since 2000 and reached 95.6% for HIV, 96.5% for syphilis, 96.2% for hepatitis B and 97% for rubella susceptibility by the second half of 2007. There is considerable variation in the performance between NHS Trusts. The overall estimated prevalence of HIV infection was 3.4/1,000 women (ranging from <1/1,000 to 10/1,000 across Trusts), of hepatitis B (HBsAg-positive) was 11.3/1,000 (2.6/1,000- 23.9/1,000), of syphilis was 4.4/1,000 (<1/1,000-16.3/1,000) and of rubella susceptibility was 39.3/1,000 (19-103/1,000). Antenatal infection screening has improved and there has been some success in implementation of national policy. However, screening uptake and prevalence of infection vary considerably across London NHS Trusts and some women are evidently disadvantaged. Improvements in information systems should help local partners to focus their interventions in those Trusts where work is still needed to increase testing as well as the capacity to monitor the uptake of screening.
Sarcopenia, myosteatosis, and weight loss as determinants of survival and toxicity in patients with resectable esophageal and gastroesophageal junction (GEJ) cancer receiving preoperative chemoradiotherapy (CRT)
Authors: A.G. Lui, A. Gallivan, M. Iafolla, Z. Abdelaziz, D. Yusuf, S. Ghosh, J. Spratlin, K. Mulder, M. Sawyer
Journal: Annals of Oncology (2017)
A phase I, open-label, nonrandomized, pharmacokinetic study of trifluridine/tipiracil (TAS-102) in Chinese patients with solid tumors.
Authors: Xicheng Wang, Jianfeng Zhou, Yan Li, Yuping Ge, Yanping Zhou, Lin Shen, Chunmei Bai
Journal: Journal of Clinical Oncology (2017)

e14079 Background: Trifluridine/tipiracil (TAS-102) is an oral combination of an antineoplastic thymidine-based nucleoside analog, trifluridine (FTD), and the thymidine phosphorylase inhibitor, tipiracil (TPI). Trifluridine/tipiracil is demonstrated as a valid treatment choice for Asian and Western patients (pts) with metastatic colorectal cancer refractory or intolerant to standard chemotherapies in earlier studies. Its pharmacokinetic (PK) profile was also investigated in American and Japanese phase 1 studies, but never in Chinese pts. This study was conducted to investigate the PK profile of Trifluridine/tipiracil in a Chinese population with solid tumors. Methods: Pts who has responded poorly to existing standard treatment received Trifluridine/tipiracil (35 mg/m 2 /dose), orally BID, on days 1-5 and days 8-12 every 4 weeks until one of discontinuation criteria was met. Blood samples for PK analysis of FTD (the active compound), fluorothymine (FTY, inactive metabolite) and TPI were collected after single and multiple doses of Trifluridine/tipiracil on days 1 and 12 of cycle 1. The safety, tolerability, and antitumor activity of Trifluridine/tipiracil were also assessed as secondary endpoints. Results: A total of 15 pts were administered Trifluridine/tipiracil and analyzed for PKs. The PKs of FTD, FTY, and TPI in Chinese pts were comparable to those in Japanese pts. Compared with American pts, although the AUC 0-t of TPI on day 12 was significantly lower in Chinese pts, the C max and AUC 0-t of FTD were not significantly different. Thirteen (86.7%) pts reported treatment-emergent adverse events (TEAEs), and eight (53.3%) pts experienced grade 3 TEAEs, of which anemia and fatigue were most frequently (≥10% of patients) reported. Grade 4 or 5 TEAEs were not observed. Conclusions: The PKs of Trifluridine/tipiracil in Chinese pts were comparable to those in Japanese pts. The exposure of FTD was showed without significant difference between Chinese, Japanese and American pts. Trifluridine/tipiracil was well-tolerated in Chinese pts and had the similar safety profile in comparison with previous studies. Clinical trial information: NCT02261532.
A Phase III, randomized, double-blind, multicenter study of adjuvant nivolumab vs placebo in patients (pts) with high-risk invasive urothelial carcinoma (UC; CheckMate 274)
Authors: D. Bajorin, M.D. Galsky, J.E. Gschwend, Y. Tomita, A. Azrilevich, F. Witjes
Journal: Annals of Oncology (2017)